Gildenberg P L
Stereotact Funct Neurosurg. 1992;59(1-4):1-8. doi: 10.1159/000098907.
Cancer pain can be successfully managed with oral or parenteral narcotics in 80% of patients, if those factors that magnify pain perception are also controlled. Pain from any source can be made worse and pain tolerance impaired by depression, regression, intolerance to stress, and/or recurrent withdrawal, all of which require attention and management. Those patients whose cancer pain is still intractable may benefit from a procedure to interrupt pain pathways. Such procedures have become far less common since the introduction of chronic administration of intraspinal narcotics. The subarachnoid route is preferable to the epidural route because it is less likely to result in catheter failure and because much smaller doses can be used, with less systemic effect. In addition, tolerance can be managed more readily by readjustment of dose with the subarachnoid route, and there is no greater incidence of complications. Intraventricular narcotics can be considered in patients whose spinal canal does not allow catheter placement, at approximately 1/10th the spinal dose requirement.
如果能同时控制那些加剧疼痛感知的因素,80%的癌症疼痛患者可通过口服或胃肠外给予麻醉药品成功得到控制。任何原因引起的疼痛都可能因抑郁、退行、对压力不耐受和/或反复停药而加重,疼痛耐受性也会受损,所有这些都需要引起关注并加以处理。那些癌症疼痛仍难以控制的患者可能会从阻断疼痛传导通路的手术中获益。自从引入慢性脊髓内给予麻醉药品后,这类手术已变得远不那么常见。蛛网膜下腔途径比硬膜外途径更可取,因为它导致导管失灵的可能性较小,而且可以使用小得多的剂量,全身作用也较小。此外,通过蛛网膜下腔途径调整剂量更容易控制耐受性,且并发症发生率并无增加。对于椎管不允许放置导管的患者,可考虑脑室内给予麻醉药品,所需剂量约为脊髓给药剂量的1/10。